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Background: The purpose of this study was to investigate the clinical characteristics of a hyporeflective space
between hyperreflective materials in pigment epithelial detachment (PED) and Bruch’s membrane in neovascular
age-related macular degeneration (AMD) using spectral-domain optical coherence tomography (SD-OCT) or swept
source optical coherence tomography (SS-OCT).
Methods: Among 223 patients with neovascular AMD, 227 eyes were studied retrospectively. Using SD-OCT or
SS-OCT, we reviewed clinical characteristics of the space.
Results: Twenty-two (10%) of the 227 eyes showed a space between hyperreflective materials in PED and Bruch’s
membrane. In all spaces, fibrovascular changes of the choroidal neovascularization (CNV) membrane were seen on
funduscopy, with OCT images showing the retinal pigment epithelium (RPE) above the space adhering tightly and
continuously to the CNV membranes. Nineteen (86%) of the 22 eyes with this cleft also had serous retinal
detachment or cystoid macular edema. Five eyes (23%) had an RPE tear during follow-up.
Conclusions: A hyporeflective space between hyperreflective materials in PED and Bruch’s membrane sometimes
appears in neovascular AMD. The appearance of such a space may indicate residual activities of the hyperreflective
materials.
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Bruch’s membraneBackground
Age-related macular degeneration (AMD) is the leading
cause of blindness in the elderly [1,2]. Recent advances
in both spectral-domain optical coherence tomography
(SD-OCT), such as improvements in registration and
averaging techniques of imaging and enhanced depth
imaging [3] and swept source optical coherence tomog-
raphy (SS-OCT), have enabled visualization of the struc-
ture of the sub-retinal pigment epithelium (RPE) in
AMD. Coscas reported finding an elevation of the RPE
and accumulation of material posterior to the RPE [4].
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unless otherwise stated.around RPE in classic choroidal neovascularization
(CNV) [5]. Polypoidal choroidal vasculopathy (PCV) is
the entity that may occur as a form of type 1 CNV [6].
The prevalence of PCV in Asians and blacks appears to
be higher than that observed in white patients [7,8]. In-
docyanine green angiography has been used to describe
polypoidal lesions and the choroidal vascular network
that lies beneath the RPE [9]. SD-OCT has demon-
strated the presence of the sub-RPE double layer sign in
the choroidal vascular network [10].
Spaide used the enhanced depth imaging-OCT tech-
nique to examine patients with pigment epithelial de-
tachment (PED) and described the internal structure of
PED associated with AMD [3]. Imaging results showed
there was a hyperreflective line that was detected on thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 A typical cleft in case with retinal angiomatous prolifetration. A hyporeflective space (cleft) between Bruch’s membrane and the
choroidal neovascularization complex (Case 10).
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http://www.biomedcentral.com/1471-2415/14/159back surface of the RPE. In addition, this study also de-
termined that PED appeared to be filled with a solid ma-
terial in 11 of 22 eyes, while 10 of 11 eyes had tissue
that seemed to be composed of layers or lamella with
clefts. Khan et al. reported finding a hyporeflective space
between the sub-RPE neovascular tissue and underlying
choroid, which they referred to as the “triple-layer” sign,
in 4 of 18 eyes with PCV [11]. Nagiel et al. demonstrated
the presence of a hyporeflective space between Bruch’s
membrane and the CNV complex in 6 of 8 eyes with an
RPE tear, which they described as a “cleft” [12]. In a pre-
vious study, we have described conformational changes
beneath the sub-RPE CNV in PED prior to developing a
RPE tear [13].
The current study used SD-OCT or SS-OCT to focus
on the hyporeflective space between hyperreflective ma-
terials in PED and Bruch’s membrane, which is referred
to as the “cleft” [3,12], and clarified the clinical charac-







Mean 74.2 ± 8.7
Range 50-92
The prevalence of the patients with
cleft in every lesion subtypes
All types 22/227 (10%)
Classic 2/38 (5%)
Occult with no classic 12/67 (18%)
Polypoidal choroidal vasculopathy 5/109 (5%)
Retinal angiomatous proliferation 3/13 (23%)Methods
We performed a retrospective medical records review of all
patients with a clinical diagnosis of neovascular AMD at
the Department of Ophthalmology of Gunma University
Medical Hospital from March 1, 2010 through December
31, 2011. This study was approved by the institutional
review board of Gunma University Graduate School of
Medicine and the research was conducted according to the
provisions of the Declaration of Helsinki, 1995 (as revised
in Edinburgh, 2000).
All patients were examined using a fundus ophthalmo-
scope, SD-OCT (Cirrus OCT; Carl Zeiss Meditec, Dublin,
CA, USA, or Spectralis OCT; Heidelberg Engineering,
Heidelberg, Germany), or SS-OCT (DRI OCT-1; Topcon,
Tokyo, Japan). SD-OCT scans were obtained using an en-
hanced depth imaging technique [3]. In addition, all pa-
tients underwent vertical, horizontal, and 3-dimensional
scans at the fovea, along with fluorescein and indocyanine
green angiography. Subtypes of AMD were classified into
four types that included: 1) typical occult CNV with no
classic component; 2) typical predominantly classic CNV;
3) PCV; or 4) retinal angiomatous proliferation (RAP). We
investigated the prevalence of the cleft sign among these
four AMD subtypes, the maximum thickness of the cleft
measured using the caliper function of the Cirrus, Spectra-
lis, or SS-OCT instruments, the maximum thickness of
the CNV membrane beyond the cleft, and the prevalence
of subretinal and retinal edema associated with the cleft.
We also evaluated features related to the number of pa-
tients with complete absorption of the cleft, recurrence
rate of the cleft, and whether the cleft was accompanied
by RPE tear. PDT with verteporfin (Visudyne; QLT,
Vancouver, Canada) was administered to patients with a
VA below 20/30, in accordance with the protocol of the
“Treatment of Age-Related Macular Degeneration with
Photodynamic Therapy Study Group” [14]. Treatment was
administered using a 689-nm laser system (Carl Zeiss
Meditec) that delivered 50 J/cm2 of energy during an
83-s exposure time. A single injection of ranibizumab
(Lucentis, 0.5 mg/0.05 ml; Genentech, South San Francisco,
Table 2 Demographic and Clinical Features of Patients with Age-Related Macular Degeneration and a Hyporeflective space between hyperreflective materials
in pigment epithelial detachment and Bruch’s membrane



















PDT with ranibizumab Case with the hyporeflective
space at initial visit
Initial VA Final VA
1 Occult + - - + - 20/250 20/200 10
2 Occult PDT with ranibizumab - + - + + 20/16 20/250 22
3 Occult PDT with ranibizumab - + - + - 20/32 20/25 22
4 Predominantly classic PDT with ranibizumab + + - - - 20/60 20/50 21
5 Occult PDT with ranibizumab - + - - - 20/60 20/200 22
6 Occult PDT with ranibizumab - + - + + 20/200 20/200 9
7 RAP PDT with ranibizumab - - - + + 20/20 20/100 21
8 Occult PDT with ranibizumab + + - + - 20/60 20/250 18
9 Occult PDT with ranibizumab - - - + - 20/80 20/1000 13
10 RAP PDT with ranibizumab - - - + - 20/80 20/60 18
11 Occult PDT with ranibizumab + + - + - 20/125 20/125 17
12 RAP PDT with ranibizumab + + + + - 20/250 20/125 18
13 Predominantly classic PDT with ranibizumab - - - - - 20/20 20/125 22
14 Occult PDT with ranibizumab - - - + - 20/30 20/40 22
15 Occult PDT with ranibizumab - + - + - 20/50 20/40 16
16 Occult PDT with ranibizumab + - + - 20/30 20/100 13
17 Occult PDT with ranibizumab + + + - 20/125 20/100 14
18 Occult PDT with ranibizumab + + - + - 20/50 20/40 13
19 PCV PDT with ranibizumab - - - + + h.m 20/30 7
20 Occult PDT with ranibizumab + - - + - 20/40 20/500 12
21 Occult PDT with ranibizumab + + - + - 20/50 20/250 22
22 Occult ranibizumab + + - + + 20/20 20/60 12
AMD = age related macular degeneration; RAP = retinal angiomatous proliferation; PCV = polypoidal choroidal vasculopathy; PDT = photodynamic therapy; SRD = serous retinal detachment; CME = cystoid macular



















Figure 2 Initial presentation of Case 10. Retinal angiomatous proliferation at the initial visit. A) A fundus photograph shows an intraretinal blot
hemorrhage at the fovea. B) Spectral-domain optical coherence tomography (vertical scan) shows subretinal fluid and cystoid macular edema
with pigment epithelial detachment. C) Fluorescence angiography shows leakage from intraretinal neovascularization and intraretinal edema. D)
Indocyanine green angiography shows intraretinal neovascularization accompanied by retinal-retinal anastomosis. The right eye was treated with
photodynamic therapy combined with three consecutive intravitreal injections of ranibizumab.
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PDT. Over the next 2 months, additional intravitreal
injections of ranibizumab were administered each month.
Ranibizumab monotherapy was used for patients with a VA
exceeding 20/30. Three ranibizumab injections were given
as a loading dose, with injections administered at approxi-
mately 4-week intervals.
When recurrent or residual exudative changes were seen
on OCT images, an additional injection of ranibizumab
was administered. In Case 6, the patient had undergone
PDT monotherapy because of cervical arterial stenosis.
A chi-square test was used to analyze whether the
prevalence of the cleft was correlated to AMD subtype.
Analysis of data was performed using SPSS version 20.0
(IBM Japan, Tokyo, Japan).
Results
Clinical characteristics of the patients are shown in
Table 1. Of the 227 eyes, 22 (10%; average year: 78.9 ±
6.8, Male: Female = 13: 9) had the cleft. Prevalence of
the cleft by lesion subtype was as follows: 12 (18%) of 67
eyes had typical occult AMD with no classic CNV, two
(5%) of 38 eyes had typical AMD with predominantly
classic CNV, five (5%) of 109 eyes had PCV, and three
(23%) of 13 eyes had RAP. A significant correlation was
seen between the four types of AMD and emergence of
the cleft sign (p = 0.007632), while the prevalence of oc-
cult AMD with no classic component and RAP tendedto be higher than that of the other two types. The super-
ior border of the cleft included the inferior edge of the
materials in PED and Bruch’s membrane, which lay
along the inferior border of the cleft. The materials in
PED were attached to the RPE monolayer along the su-
perior edge of these materials in 18 cases. In two of
three eyes with RAP and in two of 12 eyes with occult
CNV, these materials were partly detached from the RPE
monolayer at the edge of the PED. Mean maximum
thickness of the cleft was 61.2 ± 41.0 μm (range, 21-
146 μm), while mean maximum thickness of the mate-
rials above the cleft was 404.2 ± 256.5 μm (range,
129-1,042 μm). The clinical ramifications of the cleft
are summarized in Table 2. At the initial visit to our
clinic, 10 of 22 eyes had a cleft, while another 12 eyes
developed the cleft during the clinical course (Table 2).
The cleft in 14 eyes resolved or decreased with regres-
sion of the materials in PED, while the cleft remained
unchanged in seven eyes during the entire observation
period. In one eye, thickness of the cleft decreased, but
did not completely resolve. In 19 (86%) of 22 eyes with
a cleft, the patient also showed serous retinal detach-
ment (SRD) or cystoid macular edema (CME). The
cleft redeveloped in two of 14 eyes in which it had ini-
tially resolved. An RPE tear developed in five (23%)
eyes with a cleft. Figures 2, 3, 4 and 5 illustrate repre-
sentative examples of the cleft and the clinical course
before and after treatment.
Figure 3 Clinical course of the cleft in Case 10. Clinical courses of fundus and results of spectral-domain optical coherence tomography
(SD-OCT) (vertical scans) in Case 10 at 3 months after first treatment (A,B), at 24 months (C,D) and at 25 months (E,F) after first treatment. A) A
fundus photograph shows resolution of the intraretinal hemorrhage. B) SD-OCT shows absorption of the subretinal fluid (SRF) and cystoid
macular edema (CME). C) At 24 months, recurrence of SRF and CME were present at the fovea. D) SD-OCT shows a hyporeflective space between the
choroidal neovascularization (CNV) and Bruch’s membrane (cleft) (white arrows). Recurrent CME and SRF are also seen. Additional photodynamic
therapy combined with intravitreal ranibizumab injections was performed. E, F) At 1 month after additional treatment, the hyporeflective space
between the CNV and Bruch’s membrane has completely resolved. CNV beneath the retinal pigment epithelium is attached to Bruch’s membrane.
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The current study describes the clinical and conform-
ational characteristics of the cleft, which was located be-
tween the materials in PED and Bruch’s membrane in
eyes with AMD. We believe that this cleft may represent
a space that results from fluid accumulation that origi-
nates from active CNV components in the materials in
PED. The space between the materials in PED and
Bruch’s membrane that we describe here may have the
same spatial characteristics originally identified by Khan
et al. in cases with old PCV [11] and Nagiel et al. in eyes
with RPE tear [12]. Those investigators hypothesized
that the PCV lesions, the associated occult CNV, and
the remainder of Bruch’s membrane all detached from
the underlying choroid, suggesting that the polyps and
associated neovascular tissue may be more adherent tothe basal surface of the RPE than to the underlying
choroid.
Since the cleft resolved or decreased after intravitreal
injection of an anti-vascular endothelial growth factor
(anti-VEGF) agent in 12 of 22 eyes, the cleft may be
filled with exudative fluid due to leakage from the CNV
components in the materials. In the current study, 19
(86%) of 22 eyes with a cleft also had SRD or CME.
These results may support the possibility that the space
between the materials in PED and Bruch’s membrane
comprises fluid from these materials that may include
CNV membrane. In cases with a cleft, leakage from
CNV may flow anteriorly toward the retina and poster-
iorly toward Bruch’s membrane. In 10 (45%) of 22 eyes
with a cleft, we observed the clefts before treatment with
anti-VEGF agents or PDT combined with anti-VEGF
Figure 4 Initial presentation of Case 2. A typical occult AMD with no classic choroidal neovascularization (CNV) in the left eye. A, B) Fundus
photography and spectral-domain optical coherence tomography (SD-OCT) show subretinal fluid with pigment epithelial detachment at the
fovea. C) Fluorescein angiography shows occult CNV (white arrow). D) Indocyanine green angiography shows a small abnormal vascular network
(white arrow), which was treated with photodynamic therapy combined with intravitreal ranibizumab injection.
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treatments in 12 (55%) of 22 eyes. The mechanism by
which clefts develop may thus have two distinct con-
tributory factors. First, leakage from the materials that
may include CNV membrane posteriorly toward the
choroid may be an important factor. Second, contraction
of the materials, which occurs after treatment with anti-
VEGF drugs or PDT, or spontaneously, may also repre-
sent a key step. The cleft in Cases 12 and 17 resolved
after the anti-VEGF treatment, but redeveloped over
time in both of these cases. The composition of mate-
rials in PED were speculated and the components could
represent one or any combination of three materials: 1)
proteinaceous exudate; 2) fibrocellular proliferation; or
3) fibrovascular proliferation [3]. The materials in PED
in our study could also have had the same composition,
and these components may show leakage in some cases.
Because contraction of the materials in PED after
treatment with an anti-VEGF drug or PDT along with
increased tension in the RPE monolayer resulting in de-
tachment of the vascularized RPE due to leakage from
the CNV may be crucial steps in the development of
RPE tears, cases with AMD in which a cleft emergesmay need to be closely observed for the development of
RPE tear. A space between the materials beneath RPE
and Bruch’s membrane may enable the materials to
contract independently of Bruch’s membrane. Of the 22
eyes with a cleft, RPE tear developed in five eyes (23%)
after treatment. Previous studies have reported that RPE
tears developed in eyes with a highly vascularized PED
[15-18]. In fact, of the five eyes with RPE tear in the
current study, all had a large vascularized PED [3].
These results suggest that we may ascertain whether
subretinal exudate or RPE tear may follow patients with
clefts during the overall clinical course.
A histopathological study by Bressler et al. reported
finding an occult AMD lesion and a cleft between the
CNV and Bruch’s membrane in some specimens [19]. In
these specimens, the RPE monolayer and the CNV be-
neath the RPE basement membrane were shown to be
tightly adhered. However, a basal laminar deposit was
found to have intervened between the RPE monolayer
and CNV.
Tsujikawa et al. speculated that when the polypoidal
lesions in PCV have increased exudates, the fluid from
these lesions infiltrates the area under the polypoidal
Figure 5 Clinical course of the cleft in Case 2. Clinical courses of fundus and spectral-domain optical coherence tomography (SD-OCT) in Case
2 at 3 months (A, B), 6 months (C, D) and 9 months (E, F) after first treatment. A) Subretinal fluid (SRF) was decreased 3 months after first treatment
(B). A thin hyporeflective space (white arrows) developed between the sub-retinal pigment epithelium (RPE), choroidal neovascularization (CNV) and
Bruch’s membrane (cleft). C, D) The hyporeflective space thickened gradually with recurrence of SRF at 6 months after first treatment. The left eye was
then treated with additional photodynamic therapy combined with intravitreal ranibizumab injection. E) At 9 months after first treatment, although the
SRF had resolved, RPE tear developed on the temporal side of the macular region. F) SD-OCT shows disappearance of the cleft, with the regressed
sub-RPE CNV mass with corrugated RPE displaced to the opposite side of the RPE tear.
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from Bruch’s membrane and giving the appearance of being
inside the PED [20]. They reported that while the fluid was
beneath the RPE and CNV in PCV, the polypoidal lesions
beneath the sub-RPE were at the notch of the PED. How-
ever, the lesions under the RPE layer in the present study
continued uninterrupted from one side to the other of the
PED. While the location of the cleft was the same as the
space reported by Tsujikawa, the continuity of the lesions
beneath the RPE differed between these two studies.
In this study, clefts were detected in two eyes with
predominantly classic CNV. However, OCT showed that
both eyes had occult lesions. These clefts may thus have
resulted from underlying sub-RPE CNV.The limitations of the current study were the retro-
spective nature of the investigation and the small num-
ber of eyes with clefts that were examined. Further
research on the detection of clefts in a study with a lar-
ger number of patients will need to be undertaken in the
future.Conclusions
A hyporeflective space between hyperreflective materials
in PED and Bruch’s membrane can sometimes be ob-
served in patients with neovascular AMD using OCT.
The clinical characteristics of the cleft indicate that the
materials beyond the cleft may show residual activity.
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